GABA-Ergic Drugs: Exit Stage Left, Enter Stage Right
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Drugs that enhance γ-aminobutyric acid (GABA) activity by interacting at post-synaptic GABA A receptors have long been used as hypnotics, sedatives, tranquillizers and anticonvulsants. In this category, benzodiazepines rapidly gained pride of place, replacing barbiturates and becoming the most commonly prescribed of all drugs in the Western world in the 1970s. However, problems such as dependence and withdrawal reactions became apparent in the 1980s, and it seemed that the usefulness of drugs with this mode of action was limited. Recently, focus has shifted to a new group of drugs with GABA-ergic actions mediated through various mechanisms not directly involving the GABA A receptor. These drugs include gabapentin, vigabatrin, tiagabine, lamotrigine, pregabalin and others. Although originally developed as anticonvulsants for epilepsy, they appear to have wider applications for use in affective disorders, especially bipolar depression, anxiety disorders and pain conditions. The current information on the properties and therapeutic potential of this new generation of GABA-ergic drugs is reviewed. It remains to be seen whether long-term use leads to tolerance, dependence and withdrawal or discontinuation reactions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Placebo-Controlled Study of Lamotrigine and Gabapentin Monotherapy in Refractory Mood Disorders
Frye, M. A., Ketter, T. A., Kimbrell, T. A., Dunn, R. T., Speer, A. M., Osuch, E. A., Luckenbaugh, D. A., Corá-Locatelli, G., Leverich, G. S., & Post, R. M. (2000) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200012000-00004 · Cited by 446
Benzodiazepine withdrawal symptoms and propranolol
TYRER, P. (1981) · The Lancet · doi:10.1016/s0140-6736(81)92861-0 · Cited by 297
Safety Review of Adult Clinical Trial Experience with Lamotrigine
Messenheimer, J., Mullens, E. L., Giorgi, L., & Young, F. (1998) · Drug Safety · doi:10.2165/00002018-199818040-00004 · Cited by 252
Chronic use of benzodiazepines and psychomotor and cognitive test performance
Lucki, I., Rickels, K., & Geller, A. (1986) · Psychopharmacology · doi:10.1007/bf00178503 · Cited by 186
Benzodiazepine withdrawal phenomena
Hallstrom, C., & Lader, M. (2017) · International Pharmacopsychiatry · doi:10.1159/000468500 · Cited by 132
A Comparison of Buspirone and Placebo in Relieving Benzodiazepine Withdrawal Symptoms
LADER, M., & OLAJIDE, D. (1987) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-198702000-00003 · Cited by 79
Ashton, C. H., Rawlins, M. D., & Tyrer, S. P. (1990) · British Journal of Psychiatry · doi:10.1192/bjp.157.2.232 · Cited by 66
Discontinuation symptoms and psychotropic drugs
Young, A., & Haddad, P. (2000) · The Lancet · doi:10.1016/s0140-6736(05)72262-5 · Cited by 17
Self-citation
Cited by
Baldwin, D. S., Anderson, I. M., Nutt, D. J., Bandelow, B., Bond, A., Davidson, J. R. T., den Boer, J. A., Fineberg, N. A., Knapp, M., Scott, J., et al. (2005) · Journal of Psychopharmacology · doi:10.1177/0269881105059253 · Cited by 617
Anxiety in patients with epilepsy: Systematic review and suggestions for clinical management
Beyenburg, S., Mitchell, A. J., Schmidt, D., Elger, C. E., & Reuber, M. (2005) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2005.05.014 · Cited by 371
Binding, activation and modulation of Cys-loop receptors
Miller, P. S., & Smart, T. G. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.12.005 · Cited by 299
Valvassori, S. S., Elias, G., de Souza, B., Petronilho, F., Dal-Pizzol, F., Kapczinski, F., Trzesniak, C., Tumas, V., Dursun, S., Nisihara Chagas, M. H., et al. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881109106925 · Cited by 80
Targeting the Modulation of Neural Circuitry for the Treatment of Anxiety Disorders
Farb, D. H., & Ratner, M. H. (2014) · Pharmacological Reviews · doi:10.1124/pr.114.009126 · Cited by 55
Metadata
- Authors
- Ashton, H., & Young, A. H.
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2003-06
- Volume
- 17
- Issue
- 2
- Pages
- 174-178
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W2074461560
- Cited by
- 81
- References
- 8
- FWCI
- 3.00
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: GABA-Ergic Drugs: Exit Stage Left, Enter Stage Right. https://app.cochat.ai/papers/10.1177/0269881103017002004
- The paper
- Ashton, H., & Young, A. H. (2003). GABA-Ergic Drugs: Exit Stage Left, Enter Stage Right. Journal of Psychopharmacology. https://doi.org/10.1177/0269881103017002004
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.